Enterprise Value

20.6B

Cash

2.371B

Avg Qtr Burn

N/A

Short % of Float

2.02%

Insider Ownership

0.42%

Institutional Own.

92.73%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AMVUTTRA (Vutrisiran) Details
Transthyretin amyloidosis

Approved

Update

Leqvio® (inclisiran) Details
Transthyretin amyloidosis, Atherosclerotic cardiovascular disease

Approved

Quarterly sales

OXLUMO® (lumasiran) Details
Primary hyperoxaluria

Approved

Quarterly sales

ONPATTRO® (Patisiran) Details
Transthyretin amyloidosis

Approved

Quarterly sales

ONPATTRO® (Patisiran) Details
Transthyretin amyloidosis

sNDA

FDA meeting

NDA

Submission

AMVUTTRA (Vutrisiran) Details
Transthyretin amyloidosis, Cardiomyopathy

Big Mover™

Susp. Mover™

Phase 3

Data readout

ALN-TTRsc04 Details
Transthyretin amyloidosis

Phase 3

Initiation

Phase 2

Data readout

Zilebesiran (ALN-AGT) Details
Metabolic disorder, Pulmonary arterial hypertension

Phase 2

Update

ALN-HSD Details
Non-alcoholic steatohepatitis

Phase 1

Data readout

Mivelsiran (ALN-APP) Details
Alzheimer's disease, Cerebral Amyloid Angiopathy

Phase 1

Data readout

ALN-PNP Details
Non-alcoholic steatohepatitis

Phase 1

Update

ALN-KHK Details
Type 2 diabetes

Phase 1a

Data readout

ALN-XDH Details
Arthritis, Chronic refractory gout

Failed

Discontinued

Failed

Discontinued